Aptar and MGH Partner to Build Predictive Model for Nose-to-Brain Drug Delivery — AptarGroup, Inc.

Event summary

AptarGroup and Massachusetts General Hospital (MGH) have signed a research collaboration to advance nose-to-brain (N2B) drug delivery science.
The partnership aims to develop a predictive, data-driven model combining in vitro, in vivo, and computational technologies.
Aptar's nasal drug delivery systems, including Cerespray™ and Neurospray™, will be integrated into the research platform.
The collaboration seeks to address critical scientific questions about molecule suitability, transport mechanisms, and preclinical-to-human predictability.

The big picture

The collaboration between Aptar and MGH addresses a critical gap in the development of CNS therapies, where traditional drug delivery methods often fail due to the blood-brain barrier. By establishing a predictive model for nose-to-brain delivery, the partnership aims to accelerate the development of treatments for neurological diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis. This initiative is part of a broader industry shift towards non-invasive, targeted drug delivery solutions, which could significantly reduce development costs and improve patient outcomes.

What we're watching

Technology Validation: How the predictive model will perform in screening compounds for N2B delivery and whether it gains acceptance among pharmaceutical partners and regulators.
Market Adoption: The pace at which pharmaceutical innovators will integrate Aptar's N2B delivery systems into their CNS drug development pipelines.
Regulatory Alignment: Whether the NAM tool developed will align with FDA's support for New Approach Methodologies and facilitate faster regulatory approvals.